Sign In
Buy PODD
$143.30
+0.87 (+0.611%)
At Close: Jun 03, 2026
Insulet (PODD) Reports Q1 Earnings: What Key Metrics Have to Say
06:31pm, Thursday, 08'th May 2025
Although the revenue and EPS for Insulet (PODD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street
Insulet (PODD) Q1 Earnings and Revenues Surpass Estimates
06:20pm, Thursday, 08'th May 2025
Insulet (PODD) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.73 per share a year ago.
Insulet beats quarterly profit estimates on insulin pump demand
04:28pm, Thursday, 08'th May 2025
Insulet beat first-quarter profit estimates on Thursday, buoyed by strong demand for its wearable insulin pumps, sending shares up 7% in extended trading.
Curious about Insulet (PODD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
10:22am, Monday, 05'th May 2025
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qu
Insulet Names New CEO, Expects to Top Revenue Projections
10:26am, Monday, 28'th Apr 2025
Insulet (PODD) shares edged lower Monday as the maker of an insulin delivery device for diabetes patients announced a shakeup in its leadership.
Insulet Appoints Ashley McEvoy President and CEO
06:00am, Monday, 28'th Apr 2025
ACTON, Mass.--(BUSINESS WIRE)--Insulet Appoints Ashley McEvoy President and CEO.
4 Medical Product Stocks to Buy From a Challenging Industry
09:55am, Thursday, 17'th Apr 2025
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from
Strength Seen in Insulet (PODD): Can Its 7.2% Jump Turn into More Strength?
06:20am, Thursday, 10'th Apr 2025
Insulet (PODD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
5 High-Flying Large-Cap Stocks to Buy Amid Tariff-Led Market Rout
09:10am, Wednesday, 09'th Apr 2025
Despite Extreme volatility, these five stocks have provided more than 4% returns past month. These are: SFM, UNH, SRAD, GME, PODD.
PODD Stock Benefits From the Launch of Omnipod 5 in Canada
11:05am, Tuesday, 08'th Apr 2025
Insulet announces the commercial launch of Omnipod 5 AID system in Canada, with Dexcom G6 and G7 CGM sensor compatibility.
Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025
06:00am, Thursday, 03'rd Apr 2025
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced
Insulet Gains 62.9% in a Year: What's Driving the Stock?
09:10am, Monday, 24'th Mar 2025
PODD's shares rise on the back of its innovative Omnipod 5 system and impressive market expansion. However, the unfavorable macroeconomic scenario is concerning.
PODD Stock Gains Following the Launch of Omnipod 5 in Australia
01:40pm, Friday, 21'st Mar 2025
Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.
PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5
01:46pm, Thursday, 20'th Mar 2025
Insulet unveils positive RADIANT trial clinical data for its Omnipod 5 at the 18th international conference on ATTD.
ACTON, Mass.--(BUSINESS WIRE)--Insulet's RADIANT trial demonstrates meaningful glycemic improvements with Omnipod 5 AID following direct transition from multiple daily injections.
